
    
      All the patients who had neoadjuvant chemotherapy and had pathological complete response
      (pCR) or partial response to DP will enrolled in this trial. Those who had pCR will randmized
      to have two cycles of DP as adjuvant chemotherapy or have no further chemotherapy. Those
      patients who had PR will be randomized to have two cycles of DP or four cycles of CEF. All
      the patients with hormonal receptor positive or Her2 overexpress tumors are allowed to accept
      endocrine therapy or anti-Her2 target therapy.
    
  